Eutropics wins NCI contract
Eutropics will provide its BH3 profiling diagnostic assay to the NCI.
Eutropics Pharmaceuticals has been awarded a new contract to provide companion diagnostic services to the National Cancer Institute (NCI) in the US.
The agreement, signed through the institute's Small Business Initiative Research programme, will see it using its BH3 profiling diagnostic assay for treatments used in the management of patients with acute myelogenous leukaemia (AML).
The assay provides diagnostic help that can be used to inform the use of several different therapies and is currently being tested as a tool to be used alongside more experimental treatments currently in development.
It uses a biomarker that provides an understanding of whether or not cancer cells will be capable of responding to certain treatments, making it a crucial tool in deciding when to use certain treatments and which should be avoided.
"There is a very good likelihood that this BH3 profiling technology will provide an important guiding tool for treating AML," said Dr Michael Andreeff, chief of molecular hematology at MD Anderson Cancer Center and scientific advisor to Eutropics.
"We are all looking forward to its validation in the clinical studies proposed in this contract."
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...